`
`16/149,176 - GAU: 1778
`
`INFORMATION DISCLOSUREFilingDate=| 2018-10-02
`
`Gross et al
`
`C00016606US01(MED-29165/U
`
`U.S. PATENTS
`
`
`
`Examiner|Cite|Patent Kind|Issue Date Nameof Patentee or Pages, Columns, Lines where Relevant
`
`
`
`Initial |Number|CodeNo. Applicant of cited Passagesor Relevant Figures Appear
`
`Document
`praar2s2008 rayon et
`P___[2__[eararaane_[___[200a-11-09|Tayior SSS
`eS(i
`Wong SCY
`[aJeatatoen2|Wong et
`Ts__[eazasaa|Olver Favre SSS
`Ps_[asei265|Tan Stemby SCY
`Ja28687|Sternby et
`[a__[eavazes|Thompson SSS
`[fo_[ea7azaa52|Thompson SCY
`Fro[ensor7e|Gura et
`-___fri__[eoeor702_|Gura SSS
`[ra[r02sa59|Goetz SCY
`fra[rosaaas|Wong et
`Pra[rosaaa082_|Wong SSS
`Summerton SCY
`Goidau et
`re[rors]
`[7[7087620|Frank A, Gath SSS
`[fa[rr0isio|Raymond J. Wong SCY
`Fa[rios082|Wong et
`[___[20_[7is2603|Taji SSS
`[ai[7168805|Sullivan SCY
`[22[e009|Michel et
`-___[2a__[720800282_|Michel SSS
`[faa[reaiere|Karoor SCY
`as[rear|Karoor etal et
`[2s[7270082|Polascheag SSS
`Polascheggetal
`[27__[72604052|SCY
`David W. Wright
`eSee
`: et
`Mark E. Connell
`
`-___[2a_[7318802_|: SSS
`Prescient MedicalInc.
`2 SCY
`Womble et al
`6 et
`Takuji Tsukamoto
`
`[a2[745042|: SSS
`Teukameto
`Pas[raasaa052_|SCY
`Jan Peter Sternby
`[ae[rasa]
`et
`Sternby
`[as__[ras0aa7aa_|SSS
`Aabrink
`SO :
`SCY
`Masatoshi Tarumi
`[far[7557688|: et
`Tarumi et al
`[ae[755768082_|SSS
`JamesM. Brugger
`[a0[7544300|SCY
`Brugger et al
`[ao[754450082|: et
`Mitchell J. Poss
`eSCe
`:
`SSS
`Poss otal
`
`[aa[57762_|: SCY
`Malte Gross
`[aa[7568240]
`: et
`
`___[aa[756024082_|“OF. SSS
`Pas[56602|Wong SCY
`[fas[7575564]
`Childers et
`-___[ar[7507806|__|2009-70-06|Uehi SSS
`|__[#s__[75e7a0682|__|2009-10-06 ___[Uchietal SCY
`
`[aaron[aoto-ns-09—‘[wocomeieSSCS.SSSSSOSSCOSSCS
`
`
`[so_[77oaser__[__[2010-00-27[GardeSSCS.SSCS
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/DBH/
`
`Page 1/5
`
`
`
`Receipt date: 11/08/2018
`
`16/149,176 - GAU: 1778
`
`INFORMATION DISCLOSUREFilingDate=| 2018-10-02
`
`C00016606US01(MED-29165/U [sivrsesor—anesWongCOC~—CSsYSC“‘<~;‘;SCCOCOCOCOCOC™~™O...CCC‘*S
`
`PoCi*S774ass3a|2010-06-29Kelly
`PSS754852|00-07-13Burnett
`[ea[rsese[aniadARDOCOC~—SCSsSCSCOCOCOC™COCOCOC‘(NNC_CWS
`
`PoC*SSSfz77ezio|2010-08-17,[Rosenbaum
`PSS777621082|«2010-08-17,|Rosenbaumetal|CCC—C‘“‘CSCSCSCSC‘idCY
`PSC«*dS7__—[veces|Csoto-ossi_—SséBissler=SCSC*dSC(‘SSSCOCOC“‘C)CC.VVOOOOOOOO#C#(U‘(‘(S(#‘C*d
`
`[«*dS8[7veoiosiC*z0To-07_——C*dDpShan——COC~—“—sC—C—siYTSSTTTCCCCCCCOCOCOC™COiC
`PSS794i|00-09-14Perry
`
`PFS«d@0—~*77eaaia|———_—* 2010-09-14 [FrancescoPaoiniOTOCOCOCOCOCOCOCCCCC~C~C*Y
`PCi*SASf77o4atoB2[|20t0-07-14sPaolinietal,
`pC‘7850635|2010-12-14|Polaschegg|—Ci‘“‘CSsSCSCSCidzS
`
`PSS«*df@s=‘[vasoesse2|([2oto-1214—=«iPolascheggetal=—SSCSC*~iSC(‘(SSOOOOOCCOCOCOC™~™COOCCC
`PptC~“‘(cRSAizesvove[20101228Bissler
`PpCid867214|OtoChiiders
`PpS«*de=[raseest[= 2017-08-01 StembyCdSTTT
`pC‘r9ez086|2004-12Chiiders
`
`pCi“922086B2|2011-04-12Childersetal|—“C‘CSCSCSCidCS
`Peo[reazett[izooaiaMicnei—SCSC—sSCOCOCOC™COOCOCCC(NCWCS
`[«*d70‘veezortee|[eoteoai2sMicheh—SCOC—“*‘“*S*S*C=é~*idC“<‘(C;SSSSOCOCOOUTTTCC~SY
`P9779|2011-05-24[Rosenbaum|—CiCCSCid
`Pre[rearirepe[|aoit-05-24sfRosenbametal——SCidSOCSCSCSCSCSC‘C;C‘;CSCStSC*”
`PpC=*d'37955290|2011-06-07SujathaKaroor
`
`pCi*d'4795529082|2011-06-07,[Karooretal|——CiCSCSCid
`
`Ps[reseedi007idStembySCSC~—C—iSSCSCOCOCOC™COOCCCCCC“‘(‘#CW
`PpC‘“CG'=7967022—|0t06-28Grant
`Pod?ptos2|oto7-19Wang
`
`
`PS«d78—‘[voeeesa|sfpott-0802=|Tsukamoto——SSC—~—“‘—‘—C~‘dCSC“‘<;‘<;<SCS;S;7;7;7;7;7;7;CSC*d
`pCi798002726|2011-08-23[Karoo
`
`pC*BO*BOOZ726B2—|2011-08-23[Karooretal|—C—C‘CSCSCSCidS
`«Bifeozeasa[i[zois-to-oasd[KelyC—“—*~—“—s~*~*—C—‘—‘“‘YSSC‘;CSTTCTC~CCCC
`pC‘BO29454B2|2011-11-29Kellyetal
`PpC*SBOBAIST|00Gur
`PS«*d84‘[soeeess|iotrt120——=«dSuathaKaroor—SSC—~—“—*~—‘iSC“‘<‘<;<C2CS;S;7;7S;7;7CSS*~«*
`PpCtC=“‘“¥SS[80665882[2011-11-29[Karooretal
`pC=*BGs*BOVOVON|0-12.06Childers|
`
`PSC«*87[sosores|iott220SsBanter=—SSC~C—“—*‘“—*S*~sSC“‘(C;‘CSSOOOOOTTC~SY
`pC~C“‘“§SS=[8080161B2|2011-1220[Dingetal
`
`|C*'899——*8087303|2012-01-03Russell.Beavis|C—Ci‘“CSCSCidCS
`séfeos7soss2|—[zoizoi03———i[Bewvis,=CC~dESC(COC~C“CSCSCSC“‘“(®NCNC#d
`PpCtC“‘iLSN=[B096969|01201-17[Roberts
`
`|C—C“‘iR=BOQ6969B2|2012-01-17,ss[Robertsetal|—“‘C‘“CSCsCSCSC‘idCS
`fsa[avaos7a[idaie-05-15———=*dYing-Chengto—SOS—~—C‘C;~‘iTSCSSCCCOCSCCOCCCC“‘;NC*”
`PpC‘iCS=f8180574B2[2012-05-15toretal,
`PC*dsstesoas—[Ci(poros2eifC—“C;:CSCSCSCsrYSCCCOCO..V.CCCCC“‘(SC*d'
`
`P«*d96—‘sie7250[Cior205.20SsRoberts=—COC—“*‘“*—Csé‘“dSC“‘CSOOOOCOC~™COCCCSY
`PCi*d'97s818725082[|2012-05-29[Robertsetal|
`
`pCiBI974B9|0206-12Wang
`PSSC«*d(99—=‘[sieasope[faoreo6-i2——si[Wangetal—=SC~C—~‘iSC“‘C;SSSTTTC~™Y
`PCs008202247T201206-19Karakama
`
`Examiner
`Initial
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/DBH/
`
`Page 2/5
`
`
`
`Receipt date: 11/08/2018
`
`16/149,176 - GAU: 1778
`
`TENPIES|C000EEeeeeteevant
`
`
`Cite|Publicati Kind|Publicati Nan j re
`
`
`PoEDocument Figures Appear
`
`FOREIGN PATENT DOCUMENTS
`
`FOREIGNPATENTDOCUMENTS
`
`
`
`
`Examiner|Cite|Foreign Doc. |Kind|Publicaiton Nameof Patentee or|Pages, Columns, LinesCountry T
`
`
`
`
`Initial No.|Number Code|DateCode Applicant of cited where Relevant Passages or
`
`Document
`Relevant Figures Appear
`
`Include copy of this form with next communication to applicant.
`
`NON-PATENT LITERATURE DOCUMENTS
`Examiner|Cite|Include name of the author (in CAPITAL LETTERS),title of the article (when appropriate), title of the
`Initial No.|item(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`
`publisher, city and/or country where published.
`
`EXAMINER SIGNATURE
`U3i
`{Donovan Bui-Huynh/
`*EXAMINER: Initial if reference considered, whetheror not citationis in conformance with MPEP 609. Drawline throughacitation if not in conformance and not considered.
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/DBH/
`
`Page 3/5
`
`
`
`Receipt date: 11/08/2018
`
`16/149,176 - GAU: 1778
`
`Attorney Docket Number
`
`|C00016606US01(MED-29165/U
`
`CERTIFICATION STATEMENT
`That each item of information contained in the information disclosure statement wasfirst cited in any communication from a foreign patent office ina
`counterpart foreign application not more than three monthsprior to thefiling of the information disclosure statement. See 37 CFR 1.97(e}(1).
`
`That no item of information contained in the information disclosure statement was cited in a communication from a foreign patentoffice in a
`counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information
`contained in the information disclosure statement was knownto anyindividual designated in 37 CFR 1.56(c) more than three months priorto the filing
`of the information disclosure statement. See 37 CFR 1.97(e)(2).
`
`
`
`See attachedcertification statement
`A certification statement is not submitted herewith
`
`|i Thefee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`SIGNATURE
`
`Signature[RogerFanaa (YY-RINEDD
`
`Registration Number
`
`:Name/Print
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/DBH/
`
`Page 4/5
`
`
`
`Receipt date: 11/08/2018
`
`16/149,176 - GAU: 1778
`
`INFORMATION DISCLOSUREFilingDate=| 2018-10-02
`
`C00016606US01(MED-29165/U
`
`aware of a violation or potential violation of law or regulation.
`
`Privacy Act Statement
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a
`patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this
`information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by
`the U.S. Patent and TrademarkOffice is to process and/or examine your submission related to a patent application or patent. If you do not furnish the
`requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which mayresult in termination
`of proceedings or abandonmentof the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act
`(5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act
`requires disclosure of these record s.
`2. Arecord from this system of records may bedisclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative
`tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a requestinvolving an individual, to whom
`the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
`4. A record in this system of records maybe disclosed, as a routine use, to a contractor of the Agency having needfor the information in order to perform
`a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C.
`552a(m).
`5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use,
`to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C.
`181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an
`inspection of records conducted by GSAaspart of that agency's responsibility to recommend improvements in records managementpractices and
`programs, underauthority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSAregulations governing inspection of
`records for this purpose, and any otherrelevant(i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about
`individuals.
`8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C.
`122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use,
`to the public if the record wasfiled in an application which became abandonedorin which the proceedings were terminated and which application is
`referenced byeither a published application, an application open to public inspections or an issued patent.
`9. A record from this system of records may bedisclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/DBH/
`
`Page 5/5
`
`